Pneumococcal Disease Clinical Trial
Official title:
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older
This is a phase 3, randomized, double-blind, active comparator-controlled study of the safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine-naïve adults 50 years of age and older. The polyvalent (23-valent) pneumococcal vaccine, PPSV23, is the active comparator. In addition to studying safety/tolerability, it is hypothesized that, at 30 days postvaccination, the immunogenicity of V116 is noninferior to PPSV23 for the 12 common serotypes in V116 and PPSV23, and that V116 is superior to PPSV23 for the 9 serotypes unique to V116. It is also hypothesized that V116 is superior to PPSV23 in the percentage of participants with ≥4-fold rise from baseline in unique V116 serotypes, as measured by serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04546425 -
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
|
Phase 3 | |
| Recruiting |
NCT06044077 -
A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People
|
Phase 3 | |
| Completed |
NCT02146365 -
Nasopharyngeal Carriage Study in Healthy Kenyan Toddlers
|
||
| Completed |
NCT04525599 -
A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator
|
Phase 1 | |
| Active, not recruiting |
NCT05512819 -
A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan
|
Phase 3 | |
| Completed |
NCT04530838 -
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
|
Phase 3 | |
| Active, not recruiting |
NCT06026748 -
A Phase I Study of XJ103 in Chinese Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04526574 -
Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
|
Phase 3 | |
| Completed |
NCT05329259 -
A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India
|
Phase 4 | |
| Completed |
NCT00234338 -
Study Evaluating Prevenar in High-Risk Children
|
N/A | |
| Completed |
NCT01767402 -
Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults
|
Phase 1 | |
| Completed |
NCT01111214 -
Child Pneumococcal Serotype Epidemiology In Greece
|
N/A | |
| Completed |
NCT01298544 -
A Study to Assess the Antibody Response of Healthy Chinese Children Who Have Been Vaccinated Previously With 4-doses of Prevenar (a Pneumococcal Vaccine) as Babies and Toddlers
|
Phase 4 | |
| Completed |
NCT04830358 -
Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults
|
Phase 1 | |
| Completed |
NCT04379713 -
20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
|
Phase 3 | |
| Completed |
NCT04887948 -
Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
|
Phase 3 | |
| Completed |
NCT04382326 -
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
|
Phase 3 | |
| Not yet recruiting |
NCT00843895 -
Multicenter Prospective Evaluation of the Incidence and Serotyes of Invasive Pneumoccocal Disease (IPD) Among Children Below 5 Years
|
N/A | |
| Completed |
NCT01734239 -
A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)
|
Phase 3 | |
| Completed |
NCT05408429 -
Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13
|
Phase 3 |